title: Teicoplanin inhibits Ebola pseudovirus infection in cell culture.
abstract: There is currently no approved antiviral therapy for treatment of Ebola virus disease. To discover readily available approved drugs that can be rapidly repurposed for treatment of Ebola virus infections, we screened 1280 FDA-approved drugs and identified glycopeptide antibiotic teicoplanin inhibiting Ebola pseudovirus infection by blocking virus entry in the low micromolar range. Teicoplanin could be evaluated further and incorporated into ongoing clinical studies.
authors.affiliation: Unit of Anti-infective Research, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.
authors.forename: Yizhuo
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Unit of Anti-infective Research, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China; School of Life Sciences, Shanghai University, Shanghai 200444, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Cui
authors.affiliation: Unit of Anti-infective Research, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China; School of Life Sciences, Shanghai University, Shanghai 200444, China.
authors.forename: Guiming
authors.initials: G
authors.lastname: Li
authors.affiliation: Unit of Anti-infective Research, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.
authors.forename: Qianqian
authors.initials: Q
authors.lastname: Gao
authors.affiliation: Unit of Anti-infective Research, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.
authors.forename: Shilin
authors.initials: S
authors.lastname: Yuan
authors.affiliation: Unit of Anti-infective Research, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China. Electronic address: raltmeyer@ips.ac.cn.
authors.forename: Ralf
authors.initials: R
authors.lastname: Altmeyer
authors.affiliation: Unit of Anti-infective Research, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China. Electronic address: gangzou@ips.ac.cn.
authors.forename: Gang
authors.initials: G
authors.lastname: Zou
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002522:Chlorocebus aethiops; D004353:Drug Evaluation, Preclinical / Q000379:methods; D029043:Ebolavirus / Q000187:drug effects* / Q000502:physiology; D019142:Hemorrhagic Fever, Ebola / Q000188:drug therapy / Q000517:prevention & control / Q000821:virology; D057166:High-Throughput Screening Assays / Q000379:methods; D006801:Humans; D017334:Teicoplanin / Q000494:pharmacology*; D014709:Vero Cells; D053586:Virus Internalization / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D017334:Teicoplanin
keywords: Antiviral drug discovery; Ebola; High-throughput screening; Pseudovirus; Teicoplanin